Large UK Trial Finds FDA-Cleared ADHD Device Ineffective Despite Safety Profile
核心洞察
A multicenter trial with 150 children and adolescents found that trigeminal nerve stimulation (搜索) (TNS (搜索)), cleared by the FDA in 2019 for ADHD (搜索) treatment, showed no significant improvement in core symptoms compared to sham treatment.
The study revealed a substantial placebo effect, with both real and sham groups showing 26-29% symptom improvement, highlighting the importance of rigorous control conditions in neurotechnology trials.
While TNS (搜索) demonstrated excellent safety with no serious adverse events and high acceptability among participants, the findings challenge the original evidence that supported FDA clearance and suggest authorities should revisit the approval.
A comprehensive multicenter clinical trial has delivered disappointing results for trigeminal nerve stimulation (搜索) (TNS (搜索)), a non-invasive brain stimulation device cleared by the US Food and Drug Administration in 2019 as the first non-pharmacological treatment for ADHD (搜索). The study, published in Nature Medicine and led by King's College London in collaboration with the University of Southampton, found no significant therapeutic benefit from the device despite its proven safety profile.
Trial Design and Methodology
The phase 2b randomized controlled trial enrolled 150 children and adolescents aged 8-18 years with ADHD (搜索) across two UK sites. Participants were randomly assigned to receive either real TNS (搜索) or a sophisticated sham condition for four weeks of nightly treatment. The real TNS group received stimulation at 120-Hz frequency with 250-microsecond pulse width for approximately 8 hours during sleep, while the sham group received only 30 seconds of lower-frequency stimulation (2 Hz) every hour.
This design represented a significant improvement over the original pilot study that informed FDA clearance, which used no stimulation at all in the control group. The enhanced sham condition in the current trial successfully maintained blinding throughout the treatment period, with high rates of "don't know" responses from participants, parents, and researchers when asked to guess treatment allocation.
Primary Findings
The trial's primary outcome measure, parent-rated ADHD (搜索) Rating Scale (ADHD-RS) scores, showed no significant difference between groups at the four-week endpoint. The adjusted mean difference was 0.83 points (95% CI: -2.47 to 4.13; P = 0.622), indicating no evidence of differential treatment effect between real and sham TNS (搜索).
Remarkably, both groups demonstrated substantial symptom improvement during the trial period. The real TNS (搜索) group showed a 26% reduction in ADHD (搜索) symptoms, while the sham group achieved a 29% improvement. The sham group's 10-point improvement on the ADHD-RS corresponded to a large Cohen's d of 0.9, more than double the pooled effect size of 0.4 typically reported for medication versus placebo in ADHD trials.
Secondary Outcomes and Safety Profile
Most secondary outcomes also showed no significant between-group differences, with one notable exception. The Mind Excessively Wandering Scale (MEWS) demonstrated a statistically significant improvement favoring real TNS (搜索) (adjusted mean difference = -2.17; 95% CI: -4.33 to -0.01; P = 0.049). However, this finding must be interpreted cautiously given the negative results across 16 other measures and potential type I error from multiple testing.
The trial confirmed TNS (搜索)'s excellent safety profile, with no serious adverse events reported. The most common adverse device effects included headaches (real TNS: 21.3%, sham TNS: 17.3%) and sleep difficulties (real TNS: 20%, sham TNS: 9.3%). Most participants (97% of parents, 92.5% of children) reported no or only mild side effects, and acceptability was high across both groups.
Implications for Clinical Practice
Professor Katya Rubia, senior author and Professor of Cognitive Neuroscience at King's College London, emphasized the study's broader implications: "Our study shows how important it is to design an appropriate placebo condition in clinical trials of brain therapies. There is a large placebo effect with high-tech brain therapies, in particular for patients and families that have an expectation that they can adjust brain differences associated with ADHD (搜索)."
The findings contrast sharply with the original pilot study of 62 children that showed medium effect size improvements (Cohen's d = 0.5) and formed the basis for FDA clearance. The key difference lies in the improved sham condition design, which likely accounts for the successful blinding and reveals the substantial placebo effect associated with neurotechnology interventions.
Study Limitations and Future Directions
The trial faced some limitations, including high rates of missing teacher rating data (80%) due to low participation, which prevented analysis of classroom behavior changes. Additionally, while adherence was excellent at 93.3%, it relied on self-reported sleep diaries rather than objective device monitoring.
Professor Samuele Cortese from the University of Southampton noted the study's clinical significance: "Rigorous evidence, such as that generated by this study, is essential for supporting shared decision-making regarding interventions for ADHD (搜索). It empowers individuals with ADHD and their families to make informed choices about the treatment of ADHD."
The research highlights the critical importance of robust control conditions in neurostimulation research and suggests that regulatory authorities should revisit the evidence supporting TNS (搜索) approval for ADHD (搜索) treatment. While TNS remains a safe intervention with high patient acceptability, the lack of demonstrated efficacy raises questions about its clinical utility for pediatric ADHD management.